Provided by Tiger Trade Technology Pte. Ltd.

Apogee Therapeutics

135.08
+0.11000.08%
Pre-market: 135.100.0200+0.01%04:26 EDT
Volume:1.81M
Turnover:244.68M
Market Cap:10.18B
PE:-31.12
High:135.08
Open:135.00
Low:134.99
Close:134.97
52wk High:135.08
52wk Low:35.39
Shares:75.34M
Float Shares:58.14M
Volume Ratio:1.71
T/O Rate:3.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3400
EPS(LYR):-4.2155
ROE:-32.46%
ROA:-20.30%
PB:8.52
PE(LYR):-32.04

Loading ...

Street View: Strength in AbbVie's Immunology Pipeline to Support Revenue Growth

Reuters
·
Aug 03

Sector Update: Healthcare

MT Newswires Live
·
Aug 01

AbbVie Lowers Outlook to Account for Acquisition, as 2Q Profit Jumps

Dow Jones
·
Jul 31

Abbvie Shares Down 3.6% Premarket After Co Cuts 2026 Profit Forecast on Apogee Buy

THOMSON REUTERS
·
Jul 31

AbbVie Trims 2026 Profit Forecast on Apogee Buy, Beats Second-quarter Estimates

Reuters
·
Jul 31

Why Healthcare Stocks Look Like a Haven in This Market

Dow Jones
·
Jul 17

Press Release: $hareholder Alert: the M&A Class Action Firm Launches Legal Inquiry for the Merger

Dow Jones
·
Jul 15

Apogee Therapeutics CEO Michael Thomas Henderson Disposes of USD 2.67 Million in Common Shares

Reuters
·
Jul 11

Apogee Therapeutics CMO Carl Dambkowski Sells 5,500 Common Shares Worth $730,070

Reuters
·
Jul 03

Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says

MT Newswires Live
·
Jul 01

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Apogee Therapeutics (APGE)

TIPRANKS
·
Jun 29

Healthcare Stocks Have Become a Haven for Investors Ditching Tech

Dow Jones
·
Jun 27

Apogee Therapeutics CEO Michael Thomas Henderson Sells 80,000 Shares for $10.6 Million

Reuters
·
Jun 25

Apogee Therapeutics Cut to Neutral from Buy by Guggenheim

Dow Jones
·
Jun 24

Apogee Therapeutics downgraded to Hold from Buy at Stifel

TIPRANKS
·
Jun 24

Apogee Therapeutics Inc : Mizuho Cuts to Neutral from Outperform; Raises Target Price to $135 from $110

THOMSON REUTERS
·
Jun 24

Mizuho Downgrades Apogee Therapeutics to Neutral From Outperform, Lifts Price Target to $135 From $110 Amid AbbVie Deal

MT Newswires Live
·
Jun 24

Apogee Therapeutics downgraded to Neutral from Outperform at Mizuho

TIPRANKS
·
Jun 24

U.S. Research Roundup-bank of America, Fedex, Jpmorgan

Reuters
·
Jun 24

Apogee Therapeutics Inc : TD Cowen Cuts to Hold From Buy

THOMSON REUTERS
·
Jun 24